Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc reports that on 10 April 2026 it repurchased 325,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. The shares were bought at prices between 2,157.00p and 2,196.00p, with a volume-weighted average price of 2,182.28p, and will be held as treasury shares.
Since 17 February 2026, GSK has bought 18,221,521 ordinary shares. Following this latest transaction, it holds 258,112,615 shares in treasury and has 4,058,078,154 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.36% of voting rights, a figure shareholders can use when assessing notification thresholds.
GSK plc reports that on 10 April 2026 it repurchased 325,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. The shares were bought at prices between 2,157.00p and 2,196.00p, with a volume-weighted average price of 2,182.28p, and will be held as treasury shares.
Since 17 February 2026, GSK has bought 18,221,521 ordinary shares. Following this latest transaction, it holds 258,112,615 shares in treasury and has 4,058,078,154 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.36% of voting rights, a figure shareholders can use when assessing notification thresholds.
GSK plc reports routine insider share acquisitions linked to its Share Reward Plan. Several senior executives and persons closely associated with them acquired small numbers of GSK ordinary shares of 31¼ pence each through the automatic reinvestment of dividends paid on 9 April 2026.
Transactions were executed on the London Stock Exchange at prices of £21.3387 and £21.5039 per share, with individual amounts ranging from low single-digit shares to just over 1,000 shares. These acquisitions reflect dividend reinvestment rather than open-market buying decisions.
GSK plc reports routine insider share acquisitions linked to its Share Reward Plan. Several senior executives and persons closely associated with them acquired small numbers of GSK ordinary shares of 31¼ pence each through the automatic reinvestment of dividends paid on 9 April 2026.
Transactions were executed on the London Stock Exchange at prices of £21.3387 and £21.5039 per share, with individual amounts ranging from low single-digit shares to just over 1,000 shares. These acquisitions reflect dividend reinvestment rather than open-market buying decisions.
GSK plc reports that on 09 April 2026 it repurchased 330,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing buyback programme. The volume-weighted average price was 2,139.38p, with prices between 2,124.00p and 2,158.00p per share.
The repurchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought 17,896,521 ordinary shares. After this transaction, it holds 257,787,615 ordinary shares in treasury and has 4,058,396,834 ordinary shares in issue, all carrying voting rights.
GSK states that the total number of voting rights is 4,058,396,834 and confirms that, following this purchase, ordinary shares held in treasury represent 6.35% of its voting rights.
GSK plc reports that on 09 April 2026 it repurchased 330,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing buyback programme. The volume-weighted average price was 2,139.38p, with prices between 2,124.00p and 2,158.00p per share.
The repurchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought 17,896,521 ordinary shares. After this transaction, it holds 257,787,615 ordinary shares in treasury and has 4,058,396,834 ordinary shares in issue, all carrying voting rights.
GSK states that the total number of voting rights is 4,058,396,834 and confirms that, following this purchase, ordinary shares held in treasury represent 6.35% of its voting rights.
GSK plc reports that, acting through BNP Paribas, it repurchased 330,000 ordinary shares on 08 April 2026 as part of its existing share buyback programme. The shares, each with a nominal value of 31¼ pence, were bought at prices between 2,105.00p and 2,140.00p per share, with a volume‑weighted average price of 2,125.45p.
The repurchased shares will be held as Treasury shares. Since 17 February 2026, the company has bought back 17,566,521 ordinary shares. After this transaction, GSK holds 257,457,615 shares in treasury and has 4,058,726,834 ordinary shares in issue, which is also the total number of voting rights. The company states that treasury shares now represent 6.34% of voting rights, a figure relevant for shareholders’ disclosure calculations under UK rules.
GSK plc reports that, acting through BNP Paribas, it repurchased 330,000 ordinary shares on 08 April 2026 as part of its existing share buyback programme. The shares, each with a nominal value of 31¼ pence, were bought at prices between 2,105.00p and 2,140.00p per share, with a volume‑weighted average price of 2,125.45p.
The repurchased shares will be held as Treasury shares. Since 17 February 2026, the company has bought back 17,566,521 ordinary shares. After this transaction, GSK holds 257,457,615 shares in treasury and has 4,058,726,834 ordinary shares in issue, which is also the total number of voting rights. The company states that treasury shares now represent 6.34% of voting rights, a figure relevant for shareholders’ disclosure calculations under UK rules.
GSK plc reports that, acting through BNP Paribas, it repurchased 335,000 ordinary shares of 31¼ pence each on 7 April 2026 as part of its existing share buyback programme.
The shares were bought at prices between 2,084.00p and 2,134.00p, with a volume‑weighted average price of 2,113.08p, and will be held as Treasury shares.
Since 17 February 2026, GSK has bought 17,236,521 shares under this programme. After this latest purchase, it holds 257,127,615 shares in treasury and has 4,059,056,834 shares in issue (excluding treasury), which equals 4,059,056,834 voting rights. Treasury shares represent 6.33% of total voting rights under DTR 5.5.1R.
GSK plc reports that, acting through BNP Paribas, it repurchased 335,000 ordinary shares of 31¼ pence each on 7 April 2026 as part of its existing share buyback programme.
The shares were bought at prices between 2,084.00p and 2,134.00p, with a volume‑weighted average price of 2,113.08p, and will be held as Treasury shares.
Since 17 February 2026, GSK has bought 17,236,521 shares under this programme. After this latest purchase, it holds 257,127,615 shares in treasury and has 4,059,056,834 shares in issue (excluding treasury), which equals 4,059,056,834 voting rights. Treasury shares represent 6.33% of total voting rights under DTR 5.5.1R.
GSK plc reports that on 2 April 2026 it repurchased 335,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. Prices ranged from 2,093.00p to 2,161.00p per share, with a volume‑weighted average price of 2,121.37p.
The acquired shares will be held as Treasury shares. Since 17 February 2026, GSK has bought back 16,901,521 ordinary shares. After this transaction, it holds 256,792,615 shares in treasury and has 4,059,387,166 ordinary shares in issue excluding treasury, which is also the total number of voting rights. The percentage of voting rights attributable to treasury shares is confirmed at 6.33%.
GSK plc reports that on 2 April 2026 it repurchased 335,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. Prices ranged from 2,093.00p to 2,161.00p per share, with a volume‑weighted average price of 2,121.37p.
The acquired shares will be held as Treasury shares. Since 17 February 2026, GSK has bought back 16,901,521 ordinary shares. After this transaction, it holds 256,792,615 shares in treasury and has 4,059,387,166 ordinary shares in issue excluding treasury, which is also the total number of voting rights. The percentage of voting rights attributable to treasury shares is confirmed at 6.33%.
GSK plc reports that it bought back 345,000 ordinary shares of 31¼ pence each on 01 April 2026 through BNP Paribas under its existing share buyback programme. The volume-weighted average price paid was 2,106.14p per share, within a range of 2,086.00p to 2,122.00p.
The repurchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought 16,566,521 ordinary shares under this programme. After this transaction, GSK holds 256,457,615 ordinary shares in treasury and has 4,059,722,166 ordinary shares in issue, which equals the total number of voting rights.
GSK states that, in line with DTR 5.5.1R, the voting rights attributable to ordinary shares held in treasury represent 6.32 per cent. Shareholders can use the 4,059,722,166 voting rights figure as the denominator when assessing disclosure thresholds under the UK Financial Conduct Authority’s rules.
GSK plc reports that it bought back 345,000 ordinary shares of 31¼ pence each on 01 April 2026 through BNP Paribas under its existing share buyback programme. The volume-weighted average price paid was 2,106.14p per share, within a range of 2,086.00p to 2,122.00p.
The repurchased shares will be held as Treasury shares. Since 17 February 2026, GSK has bought 16,566,521 ordinary shares under this programme. After this transaction, GSK holds 256,457,615 ordinary shares in treasury and has 4,059,722,166 ordinary shares in issue, which equals the total number of voting rights.
GSK states that, in line with DTR 5.5.1R, the voting rights attributable to ordinary shares held in treasury represent 6.32 per cent. Shareholders can use the 4,059,722,166 voting rights figure as the denominator when assessing disclosure thresholds under the UK Financial Conduct Authority’s rules.
GSK plc reported that its Chief People Officer, Diana Conrad, acquired American Depositary Shares (ADS) under a GSK pension plan. She acquired 428.137 ADS at $52.0278 per ADS on 2026-03-24 and 12.186 ADS at $54.4682 per ADS on 2026-03-30 on the New York Stock Exchange.
GSK plc reported that its Chief People Officer, Diana Conrad, acquired American Depositary Shares (ADS) under a GSK pension plan. She acquired 428.137 ADS at $52.0278 per ADS on 2026-03-24 and 12.186 ADS at $54.4682 per ADS on 2026-03-30 on the New York Stock Exchange.
GSK plc reported its total voting rights as of 31 March 2026. The company had 4,316,179,781 issued ordinary shares of 31 ¼ pence each, with 256,112,615 shares held in treasury. This leaves 4,060,067,166 voting rights, which shareholders can use as the denominator for disclosure threshold calculations under UK transparency rules.
GSK plc reported its total voting rights as of 31 March 2026. The company had 4,316,179,781 issued ordinary shares of 31 ¼ pence each, with 256,112,615 shares held in treasury. This leaves 4,060,067,166 voting rights, which shareholders can use as the denominator for disclosure threshold calculations under UK transparency rules.
GSK plc reports that, acting through BNP Paribas, it repurchased 340,000 ordinary shares of 31¼ pence each on 31 March 2026 as part of its existing share buyback programme. Prices ranged from 2,064.00p to 2,086.00p per share, with a volume-weighted average price of 2,075.26p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought back 16,221,521 ordinary shares. After this transaction, GSK holds 256,112,615 shares in treasury and has 4,060,067,166 ordinary shares in issue, giving a total of 4,060,067,166 voting rights. Treasury shares represent 6.31% of the company’s voting rights under DTR 5.5.1R.
GSK plc reports that, acting through BNP Paribas, it repurchased 340,000 ordinary shares of 31¼ pence each on 31 March 2026 as part of its existing share buyback programme. Prices ranged from 2,064.00p to 2,086.00p per share, with a volume-weighted average price of 2,075.26p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought back 16,221,521 ordinary shares. After this transaction, GSK holds 256,112,615 shares in treasury and has 4,060,067,166 ordinary shares in issue, giving a total of 4,060,067,166 voting rights. Treasury shares represent 6.31% of the company’s voting rights under DTR 5.5.1R.